THU0420 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in BASDAI in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 341.1-341
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 608.1-608
2017 ◽
Vol 76
(6)
◽
pp. AB47
2017 ◽
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 346.1-346
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 355.3-356
◽
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 90.2-91
◽
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 742.2-743
◽
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 133-134
◽